WO2008090209A2

WO2008090209A2 - Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders

Info

Publication number: WO2008090209A2
Application number: PCT/EP2008/050850
Authority: WO
Inventors: Marion Wienrich; Juergen Reess
Original assignee: Boehringer Ingelheim International Gmbh
Priority date: 2007-01-26
Filing date: 2008-01-25
Publication date: 2008-07-31
Also published as: CL2008000223A1; AR065034A1; TW200843785A; WO2008090209A3

Abstract

The present invention relates to the use of a glucopyranosyloxy-pyrazole as defined in claim 1 for the manufacture of a medicament for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof.

Description

Methods for preventing and treating neurodegenerative disorders

The present invention relates to methods for preventing and treating neurodegenerative disorders in patients in need thereof by administering a pharmaceutical composition comprising a compound of general formula I

wherein the groups R¹ to R⁶ and R^7a, R^7b, R^7c are defined hereinafter, including the tautomers, the stereoisomers, the mixtures thereof and the salts thereof. In addition the present invention relates to the use of a compound of general formula I according to this invention for preparing a pharmaceutical composition for preventing and treating neurodegenerative disorders.

Background of the Invention

Pyrazole-O-glycoside derivatives inhibit the sodium-dependent glucose cotransporters (SGLT), in particular SGLT2. Reuptake of filtered glucose across epithelial cells of the kidney proceeds via sodium-dependent glucose cotransporters (SGLTs) located in the brush-border membranes in the proximal tubuli along the sodium gradient ⁽¹⁾. There are at least 3 SGLT isoforms that differ in their expression pattern as well as in their physico-chemical properties ⁽²⁾. SGLT2 is exclusively expressed in the kidney ⁽³⁾. Under normoglycemia, glucose is completely reabsorbed by SGLTs in the kidney, whereas the reuptake capacity of the kidney is saturated at glucose concentrations higher than 1OmM, resulting in glucosuria ("diabetes mellitus"). This threshold concentration can be decreased by SGLT2-inhibition. Renal filtration and reuptake of glucose contributes, among other mechanisms, to the steady state plasma glucose concentration and can therefore serve as an antidiabetic target. Therefore the pyrazole-O- glycoside derivatives are proposed as inducers of urinary sugar excretion and as medicaments in the treatment of diabetes. (1 ) Wright, E.M. (2001 ) Am. J. Renal Physiol. 280, F10-F18;

(2) Wright, E.M. et al. (2004) Pflugers Arch. 447(5):510-8;

(3) You, G. et al. (1995) J. Biol. Chem. 270 (49) 29365-29371 ;

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by multiple cognitive deficits including worsening of memory, judgement, and comprehension and deterioration in global functioning. As the disease progresses, motor, sensory, and linguistic abilities are also affected until there is global impairment of multiple cognitive functions. These cognitive losses occur gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years. Current treatments are not efficacious in every patient.

Therefore there is an unmet medical need for drugs with a good efficacy with regard to the treatment, prevention or slowing, delaying or reversing progression of neurodegenerative disorders, such as dementia, in particular dementia of Alzheimer type, while at the same time showing an improved safety profile.

Aim of the invention

An aim of the present invention is to find a new method for treating of neurodegenerative disorders, in particular of a dementia.

Another aim of the present invention is to find a new method for preventing or slowing, delaying or reversing progression of neurodegenerative disorders, in particular of a dementia.

A further aim of the present invention is to find a new therapeutic use of a glucopyranosyloxy- pyrazole derivative.

A further aim of the present invention is to provide new pharmaceutical compositions which are suitable for the treatment of neurodegenerative disorders, in particular dementia.

Other aims of the present invention will become apparent to the skilled man directly from the foregoing and following remarks.

Object of the invention

In a first aspect the present invention relates to a method for treating of one or more neurodegenerative disorders in a patient in need thereof wherein said method comprises administering a glucopyranosyloxy-pyrazole of general formula (I)

wherein

R¹ denotes hydrogen, Ci_-6-alkyl, a Ci_-4-alkyl group substituted by 1 to 3 fluorine atoms, a C_2- ₄-alkyl group substituted by a hydroxy or a Ci_-3-alkoxy group, C_3-6-alkenyl, C_3-6-cycloalkyl, Cs-β-cycloalkyl-d-s-alkyl, C_3-6-alkynyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranyl-Ci_-3-alkyl, or tetrahydropyranyl-Ci_-3-alkyl, and

R² denotes Ci_-4-alkyl, a Ci_-4-alkyl group substituted by 1 to 3 fluorine atoms, or C_3-6- cycloalkyl, and

R³ denotes hydrogen, fluorine, chlorine, bromine, Ci_-6-alkyl, C_2-6-alkenyl, C_2-6-alkynyl, C_3-6- cycloalkyl, Cs-e-cycloalkylidenemethyl, Ci_-6-alkoxy, Cs-6-cycloalkyl-oxy, C_3-6-cycloalkyl-Ci. 3-alkoxy, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, a C_2-4-alkyl or C_2-4-alkoxy group substituted by 1 to 5 fluorine atoms, a Ci_-4-alkyl group substituted by a cyano group, a Ci_-4-alkyl group substituted by a hydroxy or Ci_-3-alkyloxy group, cyano, carboxy, Ci_-3-alkoxycarbonyl, nitro, amino, Ci_-3-alkylamino, di-(Ci_-3-alkyl)amino, tetra- hydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl- Ci_-3-alkoxy, tetrahydropyranyl-Ci_-3-alkoxy, and

R⁴ and R⁵, which may be identical or different, represent hydrogen, fluorine, chlorine, bromine, Ci_-3-alkyl, Ci_-3-alkoxy, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, and

R^b , R'^a, - A - R^7b, R^7c independently of one another have a meaning selected from the group hydrogen, (Ci_-8-alkyl)carbonyl, (Ci_-8-alkyl)oxycarbonyl, arylcarbonyl and aryl-(Ci_-3-alkyl)- carbonyl,

while the aryl groups mentioned in the definition of the above groups are meant to indicate a phenyl group which may be mono- or disubstituted independently of one another by R_h, while the substituents may be identical or different and R_h denotes a fluorine, chlorine, bromine, iodine, C-ι-3-alkyl, difluoromethyl, trifluoromethyl, d-3-alkoxy, difluoromethoxy, trifluoromethoxy or cyano,

while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched,

a tautomer thereof, a stereoisomer thereof, a mixture of compounds of formula (I) or a salt thereof,

to the patient in need thereof.

In a further aspect the present invention relates to a method for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof wherein said method comprises administering a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined hereinbefore and hereinafter to the patient in need thereof.

Another aspect of the present invention relates to the use of a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined hereinbefore and hereinafter for the manufacture of a medicament for the treatment of one or more neurodegenerative disorders.

Another aspect of the present invention relates to the use of a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as hereinbefore and hereinafter for the manufacture of a medicament for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders.

Another aspect of the present invention relates to a pharmaceutical composition for the treatment of one or more neurodegenerative disorders comprising a glucopyranosyloxy- pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined hereinbefore and hereinafter.

Another aspect of the present invention relates to a pharmaceutical composition for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders comprising a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined hereinbefore and hereinafter.

Detailed Description of the invention

Unless otherwise stated the groups, residues and substituents, particularly R¹ to R⁶ and R^7a, R^7b, R^7c, are defined as above and hereinafter.

If residues, substituents or groups occur several times in a compound, they may have the same or different meanings.

The group R¹ preferably denotes hydrogen, Ci_-4-alkyl, a Ci_-3-alkyl group substituted by 1 to 3 fluorine atoms, C_3-6-cycloalkyl, Cs-e-cycloalkyl-methyl, C_3-6-alkynyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranyl-methyl, tetrahydropyranyl-methyl.

Even more preferred meanings of the group R¹ are H, methyl, ethyl, n-propyl, i-propyl, 2- propyn-1-yl, 2-butyn-1-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl and tetrahydropyranylmethyl.

Preferred meanings of the group R² according to the invention are methyl and trifluoromethyl, particularly methyl.

Preferred meanings of the group R³ are hydrogen, fluorine, chlorine, methyl, ethyl, isopropyl, tert. -butyl, 2-cyano-2-propyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, 1 ,1 ,2,2- tetrafluoroethoxy, cyclopropyl-oxy, cyclobutyl-oxy, cyclopentyl-oxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethyloxy, tetrahydropyranyl-methyloxy, ethynyl.

Most particularly preferred meanings of the group R³ are fluorine, chlorine, methyl, ethyl, isopropyl, tert. -butyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, isopropoxy, difluoromethoxy, trifluoromethoxy. Preferred meanings of the group R⁴ are hydrogen and fluorine.

Preferred meanings of the group R⁵ are hydrogen and fluorine.

Preferably R⁴ or R⁵ denotes fluorine.

The group R⁶ according to the invention preferably denotes hydrogen, (Ci_-8-alkyl)oxycarbonyl or d-β-alkylcarbonyl, particularly H or (Ci_-6-alkyl)oxycarbonyl, particularly preferably H, methoxycarbonyl or ethoxycarbonyl.

The substituents R^7a, R^7b, R^7c independently of one another preferably represent hydrogen or (Ci_-8-alkyl)carbonyl, particularly hydrogen or (Ci_-8-alkyl)carbonyl, particularly preferably hydrogen, methylcarbonyl or ethylcarbonyl. Most preferably, R^7a, R^7b and R^7c represent hydrogen.

In the methods, uses and pharmaceutical compositions according to this invention the compounds (1 ) to (138) of the formula Il

wherein the groups R¹, R³, R⁴, R⁵ and R⁶ are defined in the following Table 1 are particularly preferred, wherein Me denotes methyl and Et denotes ethyl.

Table 1

Some terms used above and hereinafter to describe the compounds according to the invention will now be defined more closely.

The term halogen denotes an atom selected from the group consisting of F, Cl, Br and I, particularly F, Cl and Br.

The term Ci_-n-alkyl, wherein n may have a value of 2 to 8, denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc..

The term Ci_-n-alkylene, wherein n may have a value of 2 to 8, denotes a saturated, branched or unbranched hydrocarbon bridge with 1 to n C atoms. Examples of such groups include methylene (-CH₂-), ethylene (-CH₂-CH₂-), 1-methyl-ethylene (-CH(CH₃)-CH₂-), 1 ,1-dimethyl- ethylene (-C(CHs)₂-CH₂-), n-prop-1 ,3-ylene (-CH₂-CH₂-CH₂-), 1-methylprop-1 ,3-ylene (- CH(CHa)-CH₂-CH₂-), 2-methylprop-1 ,3-ylene (-CH₂-CH(CH₃)-CH₂-), etc., as well as the corresponding mirror-symmetrical forms.

The term C_2-n-alkenyl, wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C=C-double bond. Examples of such groups include vinyl, 1-propenyl, 2-propenyl, iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1- propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc..

The term C_2-n-alkynyl, wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C≡C triple bond. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 2-methyl-1-propynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5- hexynyl etc..

The term Ci_-n-alkoxy or Ci_-n-alkyloxy denotes a Ci_-n-alkyl-0 group, wherein Ci_-n-alkyl is as hereinbefore defined. Examples of such groups include methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy etc..

The term Ci_-n-alkylcarbonyl denotes a Ci_-n-alkyl-C(=O) group, wherein Ci_-n-alkyl is as hereinbefore defined. Examples of such groups include methylcarbonyl, ethylcarbonyl, n- propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl, tert- butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl, n- hexylcarbonyl, iso-hexylcarbonyl, etc..

The term C_3-n-cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic group with 3 to n C atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.. Preferably the term C_3-7-cycloalkyl denotes saturated monocyclic groups.

The term C_5-n-cycloalkenyl denotes a monounsaturated mono-, bi-, tri- or spirocarbocyclic group with 5 to n C atoms. Examples of such groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc. The term Cs-_n-cycloalkyloxy denotes a Cs-_n-cycloalkyl-O group, wherein C₃-_n-cycloalkyl is as hereinbefore defined. Examples of such groups include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, etc.

The term C_3-n-cycloalkylcarbonyl denotes a C_3-n-cycloalkyl-C(=O) group, wherein C_3-n- cycloalkyl is as hereinbefore defined.

The style used above and hereinafter, in which a bond of a substituent in a phenyl group is shown towards the center of the phenyl ring, denotes, unless otherwise stated, that this substituent may be bound to any free position of the phenyl ring bearing an H atom.

The compounds according to the invention may be obtained using methods of synthesis known in principle. Preferably the compounds are obtained by methods as described for example in WO 02/36602, WO 02/088157, WO 01/16147, WO 02/053573, WO 02/068439, WO 02/068440, WO 02/098893, WO 05/021566 and in the literature cited therein.

As already mentioned, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the sodium-dependent glucose cotransporter SGLT, preferably SGLT2. In addition the compounds according to the invention of general formula I and the physiologically acceptable salts thereof are potential therapeutic agents in the treatment and/or prevention of neurodegenerative disorders, in particular dementia.

Dementia is characterized by the development of multiple cognitive deficits and memory impairment. Such cognitive deficits may include one or more of aphasia, apraxia, agnosia and disturbance in executive functioning (see for example "Diagnostic and statistical manual of mental disorders", 4^th edition, American Psychiatric Association, 2000).

The compounds according to this invention are potentially valuable in the treatment of one or more neurodegenerative disorders and in preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof.

The patient whose illness or condition is to be treated or prevented according to the invention is a mammal, particularly a human being. Preferably the term patient comprises an individual diagnosed to have a neurodegenerative disorder, in particular a dementia, especially dementia of the Alzheimer type. The term patient also comprises an individual diagnosed to have an increased risk to develop a neurodegenerative disorder, in particular a dementia, especially dementia of the Alzheimer type.

In the context of this invention the term neurodegenerative disorder denotes in particular dementia. The term dementia comprises dementia of the Alzheimer type, vascular dementia, dementia in Parkinson and dementia due to other general medical conditions. Dementia due to other medical conditions comprises dementia in chorea Huntington, dystonias, degenerative ataxias, AIDS-related dementia, Creutzfeld-Jakob's syndrome, bovine spongiform encephalopathy, prion-related infections, diseases involving mitochondrial dysfunction, Down's syndrome, hepatic encephalopathy, amyotrophic lateral sclerosis, multiple sclerosis, olivoponto-cerebellar atrophy, post-operative cognitive deficit, mild cognitive impairment, hypoxia, ischaemia resulting from cardiac arrest, stroke, glioma and other tumours, attention deficit hyperactivity disorder, autism, convulsions, epilepsy, Korsakoff syndrome, depression and schizophrenia.

The course of dementia of the Alzheimer Type is characterized by gradual onset and continuing cognitive decline.

The compounds according to this invention may improve cognitive abilities and memory, in particular in a patient as defined hereinbefore. Therefore by the administration of a compound to a patient according to this invention a cognitive decline or memory impairment may be attenuated, slowed, delayed or even reversed.

The effect of the compounds according to this invention with respect to cognitive abilities, learning and memory can be tested by methods described in the literature and known to the one skilled in the art. Examples of such tests are described in the following:

Cognitive abilities, in particular those related to learning and memorizing, may be tested in the Morris water maze. The Morris water maze is a device to investigate spatial learning and memory in rodents. It consists of a large circular pool filled with opaque water in which a small escape platform is submerged underneath the water surface. During a number of training trials, animals learn to find the platform and escape from the pool, using the different extra- maze cues contained in the experimental room. Details are described by D'Hooge R. and De Deyn P.P. (2001 ) "Applications of the Morris water maze in the study of learning and memory.", Brain Research Reviews 36, 60-90.

Another method to test cognitive abilities is based on contextual fear conditioning. Classical fear conditioning is a reference task to investigate fear memory. It is assessed in operant chambers where the animals receive a mild electric shock. The association between the experimental chamber and the shock is tested 24 hours later by returning the animals in the chambers in which training occurred (context) and measuring their freezing behaviour, i.e. the tendency of the animals to remain in motionless, defensive posture. Details are described by Kim JJ. and Jung M. W. (2006) "Neural circuits and mechanisms involved in Pavlovian fear conditioning: A critical review.", Neuroscience and Biobehavioral Reviews 30, 188-202.

A further test of cognitive abilities is related to the recognition of novel objects. The test is based on differential exploration of familiar and new objects. In the first trial (T1 ), animals are exposed to two identical objects (samples) and in a second Trial (T2), two dissimilar objects, a familiar (the sample) and a new one. Increased exploration of the novel object is a measure of recognition memory. Such a test is described by Prickaerts J. et al. (2004) "Phosphodiesterase type 5 inhibition improves early memory consolidation of object information", Neurochemistry International 45, 915-928.

The aforementioned tests of cognitive abilities can also be performed with Alzheimer disease animal models, for example with a transgenic mouse model, such as the Tg2576 mice.

The dosage required to achieve the corresponding activity for treatment or prevention usually depends on the compound which is to be administered, the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to decide. Expediently, the dosage may be from 1 to 500 mg, preferably 1 to 100 mg, by intravenous route, and 1 to 1000 mg, preferably 10 to 600 mg, by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories. Examples of Formulations

The following examples of formulations, which may be obtained analogously to methods known in the art, serve to illustrate the present invention more fully without restricting it to the contents of these examples. The term "active substance" denotes a pyrazole-O-glucoside derivative according to this invention.

Example 1 : Dry ampoule containing 75 mg of active substance per 10 ml

Composition:

Active substance 75.0 mg

Mannitol 50.0 mg water for injections ad 10.0 ml

Preparation:

Active substance and mannitol are dissolved in water. After packaging the solution is freeze- dried. To produce the solution ready for use, the product is dissolved in water for injections.

Example 2: Dry ampoule containing 35 mg of active substance per 2 ml

Composition:

Active substance 35.0 mg

Mannitol 100.0 mg water for injections ad 2.0 ml

Preparation:

Active substance and mannitol are dissolved in water. After packaging, the solution is freeze- dried. To produce the solution ready for use, the product is dissolved in water for injections.

Example 3: Tablet containing 50 mg of active substance Composition:

(1 ) Active substance 50.0 mg

(2) Lactose 98.0 mg

(3) Maize starch 50.0 mg

(4) Polyvinylpyrrolidone 15.0 mg

(5) Magnesium stearate 2.0 mg

215.0 mg

Preparation: (1 ), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side. Diameter of the tablets: 9 mm.

Example 4: Tablet containing 350 mg of active substance

Preparation:

(1 ) Active substance 350.0 mg

(2) Lactose 136.0 mg

(3) Maize starch 80.0 mg

(4) Polyvinylpyrrolidone 30.0 mg

(5) Magnesium stearate 4.0 mq

600.0 mg

(1 ), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side. Diameter of the tablets: 12 mm.

Example 5: Capsules containing 50 mg of active substance Composition:

(1 ) Active substance

(2) Dried maize starch

(3) Powdered lactose

(4) Magnesium stearate

Preparation:

(1 ) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing. This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.

Example 6: Capsules containing 350 mg of active substance Composition:

(1 ) Active substance 350.0 mg

(2) Dried maize starch 46.0 mg

(3) Powdered lactose 30.0 mg (4) Magnesium stearate 4.0 mg

430.0 mg Preparation:

(1 ) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing. This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.

Example 7: Suppositories containing 100 mg of active substance Composition:

Active substance 100.0 mg

Polyethyleneglycol (M.W. 1500) 600.0 mg

Polyethyleneglycol (M.W. 6000) 460.0 mg

Polyethylenesorbitan monostearate 840.0 mg

2,000.0 mg

Claims

Patent Claims

1. Method for treating of one or more neurodegenerative disorders in a patient in need thereof wherein said method comprises administering a glucopyranosyloxy-pyrazole of general formula (I)

wherein

R¹ denotes hydrogen, Ci_-6-alkyl, a Ci_-4-alkyl group substituted by 1 to 3 fluorine atoms, a C_2-4-alkyl group substituted by a hydroxy or a Ci_-3-alkoxy group, C_3-6-alkenyl, C_3-6- cycloalkyl, Cs-ercycloalkyl-d-s-alkyl, C_3-6-alkynyl, tetrahydrofuran-3-yl, tetrahydropyran-3- yl, tetrahydropyran-4-yl, tetrahydrofuranyl-Ci_-3-alkyl or tetrahydropyranyl-Ci_-3-alkyl, and

R denotes Ci_-4-alkyl, a Ci_-4-alkyl group substituted by 1 to 3 fluorine atoms, or C_3-6- cycloalkyl, and

R³ denotes hydrogen, fluorine, chlorine, bromine, Ci_-6-alkyl, C_2-6-alkenyl, C_2-6-alkynyl, C_3-6- cycloalkyl, Cs-e-cycloalkylidenemethyl, Ci_-6-alkoxy, Cs-₆-cycloalkyl-oxy, C_3-6-cycloalkyl- Ci_-3-alkoxy, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, a C_2-4-alkyl or C_2-4-alkoxy group substituted by 1 to 5 fluorine atoms, a Ci_-4-alkyl group substituted by a cyano group, a Ci_-4-alkyl group substituted by a hydroxy or Ci_-3-alkyloxy group, cyano, carboxy, Ci_-3-alkoxycarbonyl, nitro, amino, Ci_-3-alkylamino, di-(Ci_-3-alkyl)amino, tetra- hydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl- Ci_-3-alkoxy, tetrahydropyranyl-Ci_-3-alkoxy, and R⁴ and R⁵, which may be identical or different, represent hydrogen, fluorine, chlorine, bromine, d-3-alkyl, Ci_-3-alkoxy, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, and

R⁶ , R^7a,

R^7b, R^7c independently of one another have a meaning selected from the group hydrogen, (Ci_-8-alkyl)carbonyl, (Ci_-8-alkyl)oxycarbonyl, arylcarbonyl and aryl-(Ci_-3-alkyl)- carbonyl,

while the aryl groups mentioned in the definition of the above groups are meant to indicate a phenyl group which may be mono- or disubstituted independently of one another by R_h, while the substituents may be identical or different and R_h denotes a fluorine, chlorine, bromine, iodine, Ci_-3-alkyl, difluoromethyl, trifluoromethyl, Ci_-3-alkoxy, difluoromethoxy, trifluoromethoxy or cyano,

to the patient in need thereof.

2. Method for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof wherein said method comprises administering a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 to the patient in need thereof.

3. Method according to claim 1 or 2 wherein the neurodegenerative disorder is a dementia.

4. Method according to claim 1 or 2 wherein the neurodegenerative disorder is selected from the group consisting of dementia of the Alzheimer type, vascular dementia, dementia in Parkinson and dementia due to other general medical conditions.

5. Use of a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 for the manufacture of a medicament for the treatment of one or more neurodegenerative disorders.

6. Use of a glucopyranosyloxy-pyrazole of general formula (I), a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 for the manufacture of a medicament for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders.

7. Use according to claim 5 or 6 wherein the neurodegenerative disorder is a dementia.

8. Use according to claim 5 or 6 wherein the neurodegenerative disorder is selected from the group consisting of dementia of the Alzheimer type, vascular dementia, dementia in Parkinson and dementia due to other general medical conditions.

9. Pharmaceutical composition for the treatment of one or more neurodegenerative disorders comprising a glucopyranosyloxy-pyrazole of general formula (I) as defined in claim 1.

10. Pharmaceutical composition for preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders comprising a glucopyranosyloxy-pyrazole of general formula (I) as defined in claim 1.